Cytokinetics CYTK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.36M+1,126% | $17.76M+4.9% | $1.94M+318% | $66.77M+26,715% | $1.58M+89.1% | ||
| $95.53M-2.8% | $104.4M+11.5% | $99.23M+17.3% | $112.55M+41.4% | $98.26M+20.5% | ||
| $104.9M+82.8% | —— | —— | —— | $57.37M— | ||
| —— | $91.72M+47.1% | $69.46M+22.6% | $65.72M+29.3% | $57.37M+26.1% | ||
| $3.38M+46.9% | $2.86M+20.1% | $2.68M+11.1% | $2.29M-5.0% | $2.3M-1.3% | ||
| $202.97M+29.1% | $196.12M+25.7% | $168.69M+19.4% | $178.28M+36.7% | $157.21M+23.7% | ||
| $202.97M+29.1% | $196.12M+25.7% | $168.69M+19.4% | $178.28M+36.7% | $157.21M+23.7% | ||
| -$183.62M-18.0% | -$178.37M-28.3% | -$166.76M-18.4% | -$111.51M+14.3% | -$155.63M-23.3% | ||
| -948.7%+8,908pp | -1,004.6%-183pp | -8,613.4%+21,797pp | -167%+52,111pp | -9,856.3%+5,262pp | ||
| $14.52M+63.7% | $14.27M+59.7% | $11.35M+27.2% | $11.08M-12.9% | $8.87M+24.8% | ||
| $11.02M-19.6% | $11.47M-23.6% | $10.25M-39.9% | $13M+12.5% | $13.7M+73.1% | ||
| -$206.03M-27.7% | -$183.03M-22.0% | -$306.18M-90.7% | -$134.37M+6.2% | -$161.38M-19.0% | ||
| -1,064.5%+9,156pp | -1,030.9%-145pp | -15,815%+18,860pp | -201.2%+57,356pp | -10,220.1%+6,025pp | ||
| -$1.67-22.8% | -$1.50-19.0% | -$2.55-87.5% | -$1.12+14.5% | -$1.36-2.3% | ||
| -$1.67-22.8% | -$1.50-19.0% | -$2.55-87.5% | -$1.12+14.5% | -$1.36-2.3% | ||
| 123.3M+4.0% | 120.1M+7.3% | 120M+2.0% | 119.5M+9.4% | 118.5M+16.3% | ||
| 123.3M+4.0% | 120.1M+7.3% | 120M+2.0% | 119.5M+9.4% | 118.5M+16.3% | ||
| $2.39M+51.5% | —— | —— | —— | $1.58M— | ||
| $160K— | —— | —— | —— | $0— | ||
| -$208.27M-28.4% | -$182.44M-19.2% | -$305.99M-98.5% | -$136.07M+5.4% | -$162.23M-19.1% | ||
| $1.5M+475% | $900K-25.0% | $700K0.0% | $3M+600% | -$400K— | ||
| $1.52M+133% | —— | $6.6M— | —— | -$4.58M+55.5% | ||
| -$10.94M+25.3% | $15.96M-2.7% | -$6.6M-2,806% | $6.4M+867% | -$14.64M-3,160% | ||
| -$6.21M+56.8% | $26.37M+162% | $7.62M+38.2% | $13.99M+235% | -$14.37M-158% | ||
| -$2.06M-647% | $4.2M-50.3% | -$6.28M-40.3% | $4.64M+157% | $376K-94.3% | ||
| -$1.6M-141% | —— | -$2.8M+81.6% | -$14.6M-7,400% | $3.9M— | ||
| $7.77M+63.4% | $110.71M+4,544% | $330.47M+9,549% | $78.53M-90.4% | $4.75M-95.4% | ||
| -$145.46M-10.5% | -$142.65M-118% | -$107.51M-5.9% | -$128.24M-29.1% | -$131.62M-1.6% | ||
| $18.82M+33.7% | $16.06M+17.6% | $14.97M+12.0% | $13.18M+14.0% | $14.08M+37.8% | ||
| -$1.84M-240% | —— | $167K-97.4% | -$851K-70.5% | -$541K+2.7% | ||
| -$404K-29.5% | —— | $25K+120% | -$852K-5,425% | -$312K-1,256% | ||
| $106.52M-33.1% | $345.65M+185% | $335.45M+56.5% | $222.97M-72.7% | $159.11M+11.5% | ||
| $5.93M+4.7% | $5.64M+338% | $9.35M+1,234% | $4.15M+116% | $5.66M— | ||
| $19.36M+1,126% | $17.76M+4.9% | $1.94M+318% | $66.77M+26,715% | $1.58M+89.1% | ||
| $30.39M+29.1% | $30.51M+16.2% | $30.7M+21.1% | $27.54M+11.8% | $23.55M+9.0% | ||
| -$183.62M-18.0% | -$178.37M-28.3% | -$166.76M-18.4% | -$111.51M+14.3% | -$155.63M-23.3% | ||
| -$180.24M-17.5% | -$175.51M-28.4% | -$164.08M-18.6% | -$109.22M+14.5% | -$153.33M-23.7% | ||
| -$180.24M-17.5% | -$175.51M-28.4% | -$164.08M-18.6% | -$109.22M+14.5% | -$153.33M-23.7% | ||
| -931.2%+8,779pp | -988.5%-181pp | -8,475%+21,415pp | -163.6%+51,148pp | -9,710.6%+5,128pp | ||
| -$183.62M-18.0% | -$178.37M-28.3% | -$166.76M-18.4% | -$111.51M+14.3% | -$155.63M-23.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytokinetics's revenue?
- Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
- Is Cytokinetics profitable?
- Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
- What is Cytokinetics's earnings per share?
- Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
- Where does Cytokinetics's income statement data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
